US Broker Ratings

AtriCure, Inc. (ATRC) Stock Analysis: Healthcare Innovator with a 50% Upside Potential

AtriCure, Inc. (NASDAQ: ATRC), a leading player in the healthcare sector, specializes in the development and sale of advanced medical devices for cardiac surgery. With a market capitalization of $1.64..

Viridian Therapeutics, Inc. (VRDN) Stock Analysis: A Potential 121.97% Upside in Rare Disease Innovation

For investors exploring opportunities in the biotechnology sector, Viridian Therapeutics, Inc. (NASDAQ: VRDN) presents an intriguing prospect. With a market cap of $1.41 billion, this U.S.-based company is carving a..

Biohaven Ltd. (BHVN) Stock Analysis: A 315% Potential Upside in Biotech Investment

For investors with an appetite for high-risk, high-reward opportunities, Biohaven Ltd. (NASDAQ: BHVN) presents a compelling case. The biotechnology company, headquartered in New Haven, Connecticut, is making waves in the..

Amphastar Pharmaceuticals, Inc. (AMPH) Stock Analysis: Unraveling a 44.78% Potential Upside

Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH), a notable player in the healthcare sector, particularly within the specialty and generic drug manufacturing industry, presents a compelling case for investors seeking potential growth..

Astrana Health Inc. (ASTH) Stock Analysis: Exploring a Potential 100% Upside in the Healthcare Sector

Astrana Health Inc. (NASDAQ: ASTH), a prominent player in the healthcare sector, has garnered significant attention from investors, particularly due to its potential upside of over 100%. With a market..

Progyny, Inc. (PGNY) Stock Analysis: Unpacking the 15% Upside Potential and Analyst Consensus

Progyny, Inc. (NASDAQ: PGNY) stands as a beacon of innovation within the healthcare sector, particularly in the niche of fertility and women’s health benefits. Headquartered in New York, the company’s..

Centessa Pharmaceuticals (CNTA) Stock Analysis: Exploring the 112% Potential Upside in Biotech

For investors with an eye on the biotechnology sector, Centessa Pharmaceuticals plc (NASDAQ: CNTA) presents an intriguing opportunity. Headquartered in Altrincham, United Kingdom, Centessa is a clinical-stage pharmaceutical company focused..

The Pennant Group, Inc. (PNTG) Stock Analysis: A 44.7% Upside Potential in the Healthcare Sector

For investors looking to explore opportunities within the healthcare sector, The Pennant Group, Inc. (NASDAQ: PNTG) presents a compelling case. With a focus on home health, hospice, and senior living..

Integra LifeSciences Holdings C (IART) Stock Analysis: Exploring a 21% Potential Upside in the Healthcare Sector

For investors seeking opportunities in the healthcare sector, Integra LifeSciences Holdings Corporation (NASDAQ: IART) presents a potentially intriguing option, offering a glimpse into the world of medical devices with a..

Mineralys Therapeutics, Inc. (MLYS) Stock Analysis: Exploring a Promising 166% Upside Potential

Mineralys Therapeutics, Inc. (MLYS) is emerging as a noteworthy player in the biotechnology sector, with a particular focus on addressing diseases driven by dysregulated aldosterone. This clinical-stage biopharmaceutical company is..

Innoviva, Inc. (INVA) Stock Analysis: Unpacking a Potential 117% Upside in the Biotech Sector

Innoviva, Inc. (NASDAQ: INVA) is gaining attention in the biotech industry for its promising growth prospects and strategic partnerships, despite recording a recent dip in its stock price. With a..

agilon health, inc. (AGL) Investor Outlook: Exploring an 80% Potential Upside in Healthcare

For investors with an eye on the healthcare sector, agilon health, inc. (AGL) presents a fascinating, albeit complex, opportunity. With a current market cap of $823.76 million and a share..

Evotec SE (EVO) Stock Analysis: Unlocking the Potential with a 40% Upside

Evotec SE (EVO), with its roots deeply embedded in Germany’s healthcare sector, has emerged as a significant player in the drug discovery and development landscape. The company operates on a..

Mesoblast Limited (MESO): Investor Outlook on a 69.49% Potential Upside in the Biotech Sector

Mesoblast Limited (NASDAQ: MESO), a pioneering firm in the biotechnology sector, is capturing investor attention with a potential upside of 69.49% based on analyst target price forecasts. Specializing in regenerative..

Aveanna Healthcare Holdings Inc (AVAH) Stock Analysis: Unpacking a Potential 45% Upside for Investors

Aveanna Healthcare Holdings Inc (NASDAQ: AVAH), a key player in the healthcare sector, is carving out a significant niche with its diversified home care platform in the United States. With..

Mirum Pharmaceuticals (MIRM) Stock Analysis: Unpacking a 33% Potential Upside in the Biotechnology Sector

Mirum Pharmaceuticals, Inc. (NASDAQ: MIRM) has captured investor attention with its promising strides in the biopharmaceutical landscape, particularly in developing therapies for rare and debilitating diseases. With a market cap..

Dyne Therapeutics, Inc. (DYN): Biotech Stock with a 325% Upside Potential

Dyne Therapeutics, Inc. (NASDAQ: DYN), a clinical-stage biotechnology firm, has been making waves in the healthcare sector with its cutting-edge approach to treating neuromuscular diseases. Headquartered in Waltham, Massachusetts, Dyne..

Harrow, Inc. (HROW) Stock Analysis: Eyeing a 70% Upside with Strong Buy Ratings

Harrow, Inc. (NASDAQ: HROW) is drawing significant attention from investors with its promising growth prospects in the healthcare sector, particularly within the specialty and generic drug manufacturing industry. Headquartered in..

LifeStance Health Group (LFST): Investor Outlook Highlights Over 100% Potential Upside

LifeStance Health Group, Inc. (NASDAQ: LFST), a key player in the healthcare sector’s medical care facilities industry, is attracting investor attention with its significant growth potential. With a market capitalization..

Kestra Medical Technologies (KMTS): An Investor’s Insight into Potential 62.63% Upside

Investors eyeing the healthcare sector might find Kestra Medical Technologies, Ltd. (KMTS) an intriguing opportunity, especially with the potential for a significant 62.63% upside based on current analyst ratings. This..

US Broker Ratings

US Broker Ratings

FTSE 100

Funds